[Form 4] Guardant Health, Inc. Insider Trading Activity
Guardant Health director and Chief Information Officer Kumud Kalia reported transactions on Form 4 showing restricted stock units vesting and a small open-market sale. On 09/01/2025, 711 shares were reported as acquired at a $0 price reflecting the vesting of RSUs, leaving 19,211 shares beneficially owned. The filing also shows a disposal of 361 shares on 09/01/2025 at a price of $67.42, reducing reported holdings to 18,850 shares. The RSU award was originally granted in November 2021 and vests quarterly through the three-year schedule that began 09/01/2022.
Il direttore e Chief Information Officer di Guardant Health, Kumud Kalia, ha comunicato operazioni nel Modulo 4 relative al vesting di restricted stock units e a una piccola vendita sul mercato aperto. Il 01/09/2025 sono state riportate come acquisite 711 azioni a prezzo $0 per effetto del vesting delle RSU, portando la detenzione a vantaggio a 19.211 azioni. La comunicazione segnala inoltre la cessione di 361 azioni il 01/09/2025 a $67,42, riducendo il totale dichiarato a 18.850 azioni. L鈥檃ssegnazione delle RSU era stata originariamente concessa nel novembre 2021 e matura trimestralmente secondo il programma triennale iniziato il 01/09/2022.
Kumud Kalia, director y Chief Information Officer de Guardant Health, inform贸 transacciones en el Formulario 4 que muestran el vencimiento de restricted stock units y una peque帽a venta en el mercado abierto. El 01/09/2025 se reportaron como adquiridas 711 acciones a precio $0 por el vesting de las RSU, quedando 19.211 acciones en propiedad beneficial. El informe tambi茅n registra la disposici贸n de 361 acciones el 01/09/2025 a un precio de $67.42, reduciendo la tenencia informada a 18.850 acciones. La concesi贸n de las RSU se otorg贸 originalmente en noviembre de 2021 y vence trimestralmente seg煤n el cronograma de tres a帽os iniciado el 01/09/2022.
Guardant Health鞚� 鞚挫偓 瓴� 斓滉碃鞝曤炒毂呾瀯鞛�(CIO) Kumud Kalia電� Form 4鞐� 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 氩犾姢韺呹臣 靻岇暋鞚� 鞛ル偞 毵る弰 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025-09-01鞐� RSU 氩犾姢韺呾溂搿� 711欤�臧� 旆摑(臧�瓴� $0)霅� 瓴冹溂搿� 氤搓碃霅橃柎 齑� 鞁れ 靻岇湢 欤检嫕 靾橂姅 19,211欤�臧� 霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 霕愴暅 2025-09-01鞐� 361欤�毳� 欤茧嫻 $67.42鞐� 觳橂秳頃橃棳 氤搓碃霅� 氤挫湢霟夓澊 18,850欤�搿� 臧愳唽頄堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 RSU電� 2021雲� 11鞗旍棎 斓滌磮 攵�鞐悩鞐堦碃 2022-09-01攵�韯� 鞁滌瀾霅� 3雲� 鞚检爼鞐� 霐半澕 攵勱赴氤勲 氩犾姢韺呺惄雼堧嫟.
Kumud Kalia, directeur et directeur de l'information (CIO) de Guardant Health, a d茅clar茅 des transactions sur le formulaire 4 indiquant le vesting d'unit茅s d'actions restreintes et une petite vente en bourse. Le 01/09/2025, 711 actions ont 茅t茅 signal茅es comme acquises 脿 un prix de 0 $ suite au vesting des RSU, portant la d茅tention b茅n茅ficiaire 脿 19 211 actions. Le d茅p么t indique 茅galement la cession de 361 actions le 01/09/2025 au prix de 67,42 $, r茅duisant la position d茅clar茅e 脿 18 850 actions. L'attribution des RSU avait 茅t茅 initialement accord茅e en novembre 2021 et se lib猫re trimestriellement selon le calendrier triennal d茅butant le 01/09/2022.
Kumud Kalia, Direktor und Chief Information Officer von Guardant Health, meldete Transaktionen im Formular 4, die das Vesting von Restricted Stock Units sowie einen kleinen Verkauf am offenen Markt zeigen. Am 01.09.2025 wurden infolge des RSU-Vestings 711 Aktien zu einem Preis von $0 als erworben gemeldet, womit sich der wirtschaftliche Besitz auf 19.211 Aktien belief. Die Einreichung zeigt au脽erdem die Ver盲u脽erung von 361 Aktien am 01.09.2025 zu $67,42, wodurch der gemeldete Bestand auf 18.850 Aktien sank. Die RSU-Zuteilung wurde urspr眉nglich im November 2021 gew盲hrt und vests viertelj盲hrlich gem盲脽 dem dreij盲hrigen Plan, der am 01.09.2022 begann.
- 711 RSU shares vested on 09/01/2025, reflecting scheduled compensation delivery
- Reported beneficial ownership remains substantial at 19,211 shares immediately after the vesting event
- 361 shares were sold on 09/01/2025 at $67.42, reducing holdings to 18,850 shares
Insights
TL;DR: Director sold a small number of shares and had RSUs vest; net holdings declined slightly.
The transactions are routine insider activity: vesting of previously granted restricted stock units produced 711 shares reported as acquired at no cash cost, consistent with the award schedule disclosed in the filing. A contemporaneous sale of 361 shares at $67.42 reduced the director's net ownership by 361 shares to 18,850. The scale of the sale (<2% of post-transaction holdings) appears immaterial to company capitalization.
TL;DR: Vesting and a small sale are standard executive compensation events, not indicative of governance issues.
The Form 4 documents an ordinary-course vesting event from a 2021 RSU grant and a partial disposition of shares. The filing includes the RSU vesting schedule (25% vested 09/01/2022, remainder quarterly over three years) which explains the 711-share acquisition. There is no indication of abnormal trading patterns, exceptions, or use of a 10b5-1 plan noted on the face of the form.
Il direttore e Chief Information Officer di Guardant Health, Kumud Kalia, ha comunicato operazioni nel Modulo 4 relative al vesting di restricted stock units e a una piccola vendita sul mercato aperto. Il 01/09/2025 sono state riportate come acquisite 711 azioni a prezzo $0 per effetto del vesting delle RSU, portando la detenzione a vantaggio a 19.211 azioni. La comunicazione segnala inoltre la cessione di 361 azioni il 01/09/2025 a $67,42, riducendo il totale dichiarato a 18.850 azioni. L鈥檃ssegnazione delle RSU era stata originariamente concessa nel novembre 2021 e matura trimestralmente secondo il programma triennale iniziato il 01/09/2022.
Kumud Kalia, director y Chief Information Officer de Guardant Health, inform贸 transacciones en el Formulario 4 que muestran el vencimiento de restricted stock units y una peque帽a venta en el mercado abierto. El 01/09/2025 se reportaron como adquiridas 711 acciones a precio $0 por el vesting de las RSU, quedando 19.211 acciones en propiedad beneficial. El informe tambi茅n registra la disposici贸n de 361 acciones el 01/09/2025 a un precio de $67.42, reduciendo la tenencia informada a 18.850 acciones. La concesi贸n de las RSU se otorg贸 originalmente en noviembre de 2021 y vence trimestralmente seg煤n el cronograma de tres a帽os iniciado el 01/09/2022.
Guardant Health鞚� 鞚挫偓 瓴� 斓滉碃鞝曤炒毂呾瀯鞛�(CIO) Kumud Kalia電� Form 4鞐� 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 氩犾姢韺呹臣 靻岇暋鞚� 鞛ル偞 毵る弰 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025-09-01鞐� RSU 氩犾姢韺呾溂搿� 711欤�臧� 旆摑(臧�瓴� $0)霅� 瓴冹溂搿� 氤搓碃霅橃柎 齑� 鞁れ 靻岇湢 欤检嫕 靾橂姅 19,211欤�臧� 霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 霕愴暅 2025-09-01鞐� 361欤�毳� 欤茧嫻 $67.42鞐� 觳橂秳頃橃棳 氤搓碃霅� 氤挫湢霟夓澊 18,850欤�搿� 臧愳唽頄堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 RSU電� 2021雲� 11鞗旍棎 斓滌磮 攵�鞐悩鞐堦碃 2022-09-01攵�韯� 鞁滌瀾霅� 3雲� 鞚检爼鞐� 霐半澕 攵勱赴氤勲 氩犾姢韺呺惄雼堧嫟.
Kumud Kalia, directeur et directeur de l'information (CIO) de Guardant Health, a d茅clar茅 des transactions sur le formulaire 4 indiquant le vesting d'unit茅s d'actions restreintes et une petite vente en bourse. Le 01/09/2025, 711 actions ont 茅t茅 signal茅es comme acquises 脿 un prix de 0 $ suite au vesting des RSU, portant la d茅tention b茅n茅ficiaire 脿 19 211 actions. Le d茅p么t indique 茅galement la cession de 361 actions le 01/09/2025 au prix de 67,42 $, r茅duisant la position d茅clar茅e 脿 18 850 actions. L'attribution des RSU avait 茅t茅 initialement accord茅e en novembre 2021 et se lib猫re trimestriellement selon le calendrier triennal d茅butant le 01/09/2022.
Kumud Kalia, Direktor und Chief Information Officer von Guardant Health, meldete Transaktionen im Formular 4, die das Vesting von Restricted Stock Units sowie einen kleinen Verkauf am offenen Markt zeigen. Am 01.09.2025 wurden infolge des RSU-Vestings 711 Aktien zu einem Preis von $0 als erworben gemeldet, womit sich der wirtschaftliche Besitz auf 19.211 Aktien belief. Die Einreichung zeigt au脽erdem die Ver盲u脽erung von 361 Aktien am 01.09.2025 zu $67,42, wodurch der gemeldete Bestand auf 18.850 Aktien sank. Die RSU-Zuteilung wurde urspr眉nglich im November 2021 gew盲hrt und vests viertelj盲hrlich gem盲脽 dem dreij盲hrigen Plan, der am 01.09.2022 begann.
FAQ
What transactions did Guardant Health (GH) insider Kumud Kalia report on Form 4?
How many shares does Kumud Kalia beneficially own after the reported transactions?
Were the acquired shares a purchase or vesting of restricted stock units for GH insider?
What is the vesting schedule for the RSU award mentioned in the Form 4?
Did the Form 4 indicate use of a 10b5-1 trading plan for these transactions?
